Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 160

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 1B
Chunk 160
---
    $
    (18,609
    )
     
    $
    (21,486
    )

    Net loss attributable to noncontrolling interest

    27

    7

    Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc.    to net cash used in operating activities:

    Issuance costs for common stock warrant liabilities

    688

    —

    Loss on marketable equity securities, net

    8

    176

    Accretion of income on marketable debt securities

    (229
    )

    (679
    )

    Depreciation and amortization expense

    587

    562

    Change in right-of-use assets and liabilities

    (42
    )

    91

    Amortization of intangible assets

    22

    130

    Stock-based compensation

    5,077

    4,640

    Change in fair value of warrant liability

    (2,128
    )

    —

    Deferred income tax benefit

    —

    (1,803
    )

    Foreign currency remeasurement and other loss

    273

    600

    Changes in operating assets and liabilities:

    Accounts receivable

    106

    (446
    )

    Prepaid expenses and other current assets

    489

    (418
    )

    Accounts payable and accrued liabilities

    (1,681
    )

    (2,295
    )

    Deferred revenue

    (7,680
    )

    (7,645
    )

    Net cash used in operating activities

    (23,092
    )

    (28,566
    )

    CASH FLOWS FROM INVESTING ACTIVITIES:

    Proceeds from the sale of marketable equity securities

    18

    196

    Purchases of marketable debt securities

    (8,761
    )

    (16,403
    )

    Maturities of marketable debt securities

    7,000

    63,330

    Purchase of equipment

    (565
    )

    (674
    )

    Net cash (used in) provided by investing activities

    (2,308
    )

    46,449

    CASH FLOWS FROM FINANCING ACTIVITIES:

    Proceeds from employee options exercised

    229